FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...
Eli Lilly and Novo Nordisk, obviously, didn't love the setup, but there wasn't much they could do to stop it, given the ...
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...
The Motley Fool on MSN9d
This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?When the company reported VK2735's phase 2 results last year, the stock jumped 121% in one trading session. Viking gave back ...
Vertex Pharmaceuticals’ non-opioid pain medication is up for FDA approval this week. Other drugmakers have found safer ...
The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Compounding pharmacies such as Hims & Hers Health producing their own versions of tirzepatide likely pressured demand for Eli Lilly's branded version in the second half of 2024. The Food and Drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback